Abstract: A method, apparatus and computer program product are provided for utilizing accumulation records to reduce a number of transactions occurring in a network. Aggregated quantities are calculated from at least a first quantity from a first sub-system and a second quantity from the second sub-system. Preliminary amounts may be reduced based on cap amounts less the aggregated quantity, and transmission of messages to certain sub-systems may be precluded. Accumulation records may be maintained by a service provider computer on an ongoing basis. The service provider computer forwards responses that reflect a reduced preliminary amount to a requesting computer that initiated a response.

Abstract: There are provided compounds of Formula I: various compositions thereof and methods for their use in the inhibition of ?-amylase.

Abstract: There are provided compounds of Formula I: various compositions thereof and methods for their use in the inhibition of ?-amylase.

Abstract: Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.

Abstract: A count of documents similar to a reference document is determined based on a plurality of similarity ratings. Each similarity rating may be based on a number of co-occurring terms between the reference document and the corresponding similar documents. A graphical user interface (GUI) may be provided. The GUI may include a GUI element that is associated with the similar documents. Furthermore, the GUI element may include a visual representation of a number of documents for each similarity rating that are retrievable based on a selection of the corresponding similarity rating. The GUI element may be provided prior to retrieving one of the similar documents.

Abstract: Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.

Abstract: Disclosed is a method for inhibiting the formation of foam in aqueous systems by adding foam control composition including a polyoxyethylene and/or a polyoxypropylene nonionic fatty acid derivative and a quaternary ammonium surfactant.

Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.

Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.

Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: A computing device determines counts of documents that are similar to a reference document for a set of similarity ratings. Each similarity rating is based on a number of co-occurring terms between the reference document and corresponding similar documents. The computing device present the reference document and a GUI element pertaining to the documents similar to the reference document in a graphical user interface (GUI). Upon a selection of the GUI element, the computing device presents a visual representation of a correlation between the counts of similar documents and the similarity ratings in the GUI. The visual representation is provided prior to displaying at least one of the similar documents.

Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.

Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.